Skip to main content
. 2015 Jun 19;6:125. doi: 10.3389/fphar.2015.00125

Table 2.

Examples of rapidly-progressing therapeutics.

Company Therapeutic Phase I Approval
Roche/Genentech Vemurafenib (Zelboraf™) November 2006 August 2011
Pfizer Crizotinib (Xalkori®) December 2007 August 2011
GSK Trametinib (Mekinist™) May 2008 May 2013
Roche/Genentech Ado-trastuzumab emtansine (Kadcyla®) June 2009 February 2013
GSK Dabrafenib (Tafinlar®) April 2009 May 2013